Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Xanelim BLA filing

  • News

Executive Summary

Genentech and Xoma will conduct an additional pharmacokinetics study to confirm equivalence between Xanelim (efalizumab) material used for clinical testing and commercial lots. The trial will delay the estimated BLA filing date until summer 2002. Genentech had planned to file a BLA in the first quarter of 2002 (1"The Pink Sheet" Aug. 6, p. 20)

You may also be interested in...



Genentech Xanelim Therapy Transition Study To Support Product Launch

Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.

Genentech Xanelim Therapy Transition Study To Support Product Launch

Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.

Genentech Considers Xanelim Chronic Psoriasis Therapy Indication

Genentech hopes to position Xanelim for use as a chronic therapy for moderate to severe plaque psoriasis based on six-month data.

Table

View full table

Tags:
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS038653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By